Table 5.

Summary of the various antioxidants studied for stroke/IRI

Disease	Test agent	Primary endpoint	Result/Outcome	Model	Ref
Stroke/IRI	NXY-059 (Cerovive), Tirilazoid	Post-stroke Neurological and functional outcome	Failure as a neuroprotectant, lack of functional outcome	Human	2, 83, 94
	NXY-059 (Cerovive)	Disability at 90-days	Improvement only in the primary outcome and not in neurological outcome	Human	83, 141
	Ebselen	MCA occlusion	Modest neuroprotection when given as a prophylactic dose	Rat	56
	Edaravone	Post-stroke functional outcome based on modified Rankin scale	Significant improvements in the functional outcome	Human	3
	Resveratrol	Inhibition of focal ischemia by MCA occlusion	Prevention of oxidative damage and motor impairment	Rat	94, 143

MCA: middle cerebral artery.